Hyper Corporation Inc. (KOSDAQ:065650)

South Korea · Delayed Price · Currency is KRW

2,010.00

-40.00 (-1.95%)

At close: Jul 20, 2026

-80.64% (1Y)

Market Cap	21.97B -68.2%
Revenue (ttm)	80.77B +30.1%
Net Income	-3.04B
EPS	-401.22
Shares Out	10.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,273
Open	2,050.00
Previous Close	2,050.00
Day's Range	1,942.00 - 2,050.00
52-Week Range	1,740.00 - 11,220.00
Beta	1.51
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Hyper Corporation

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and w... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services

Founded 1997

Employees 49

Stock Exchange KOSDAQ

Ticker Symbol 065650

Full Company Profile

Financial Performance

In 2025, Hyper Corporation's revenue was 76.19 billion, an increase of 32.04% compared to the previous year's 57.70 billion. Losses were -315.64 million, -99.61% less than in 2024.

Financial Statements